Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Real-World Data Topic Center

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024

Featuring Scott Swain, PhD, MPH

Featuring Scott Swain, PhD, MPH ...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Conference Coverage
The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration
12/06/2023

Edited by Grace Taylor

Edited by Grace Taylor
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world...
12/06/2023
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023

Featuring Claire Snyder, PhD, and Norah Crossnohere, PhD

Featuring Claire Snyder, PhD, and Nor...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023

Featuring Christopher D'Avella, MD

Featuring Christopher D'Avella, MD ...
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways
Smita Agrawal, PhD.
Videos
Enhancing Line of Therapy Derivation Using Real-World Data From Electronic Health Records Via Integration of Medical Claims Data
08/08/2023

Featuring Smita Agrawal, PhD

Featuring Smita Agrawal, PhD
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive...
08/08/2023
Journal of Clinical Pathways
News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022

Craig Ostroff

Craig Ostroff
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022

Craig Ostroff

Craig Ostroff
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
OCPC: In Session
Highlights of the 2022 Clinical Pathways Benchmark Survey
12/05/2022
Winston Wong, PharmD, Editor-in-Chief
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD, Editor-in-Chief, presents the highlights of the 2022 Clinical Pathways Benchmark Survey results, as presented as part of the Oncology Clinical Pathways Congress in Boston in October.
Winston Wong, PharmD,...
12/05/2022
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways

Expert Insights

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024

Featuring Scott Swain, PhD, MPH

Featuring Scott Swain, PhD, MPH ...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023

Featuring Claire Snyder, PhD, and Norah Crossnohere, PhD

Featuring Claire Snyder, PhD, and Nor...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023

Featuring Christopher D'Avella, MD

Featuring Christopher D'Avella, MD ...
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways
Smita Agrawal, PhD.
Videos
Enhancing Line of Therapy Derivation Using Real-World Data From Electronic Health Records Via Integration of Medical Claims Data
08/08/2023

Featuring Smita Agrawal, PhD

Featuring Smita Agrawal, PhD
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive director at ConcertAI, spoke about her study on deriving lines of therapy by integrating data from multiple data sources to improve accuracy.
Smita Agrawal, PhD, executive...
08/08/2023
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World Effectiveness of Rituximab Maintenance Among Older Patients With Mantle Cell Lymphoma
06/15/2022
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates real-world treatment patterns and assesses the efficacy of rituximab maintenance following standard chemoimmunotherapy among older patients with MCL.
Mengyang Di, MD, PhD, evaluates...
06/15/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Ethan Sokol, PhD
Videos
Real-World Outcomes of HR-Positive HER2-Negative Metastatic Breast Cancer Treated With ICIs
10/21/2021
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses real-world time-to-treatment-discontinuation for patients with high tumor mutational burden HR-positive and HER2-negative breast cancer who were treated with immune checkpoint inhibitors.
Ethan Sokol, PhD, discusses...
10/21/2021
Journal of Clinical Pathways
Geoffrey Oxnard, MD
Videos
Real-World Testing and Treatment Patterns in Advanced NSCLC
10/18/2021
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares treatment regimens for patients with advanced NSCLC prior to receipt of comprehensive genomic profiling vs after receipt of comprehensive genomic profiling in the real-world setting.
Geoffrey Oxnard, MD, compares...
10/18/2021
Journal of Clinical Pathways
Weija Wang
Videos
Real-World Outcomes of Febrile Neutropenia Among Patients With Breast Cancer or Non-Hodgkin Lymphoma
05/27/2021
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses results from a study examining the association of demographics, comorbidities, chemotherapy regimen, and risk factors on the risk of developing febrile neutropenia in the first cycle of receiving pegfilgrastim...
Weijia Wang, MSc, discusses...
05/27/2021
Journal of Clinical Pathways
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
Blog
CPC + CBEx: Breaking down barriers and pushing boundaries of cancer care
08/07/2024
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together stakeholders invested throughout the entire patient journey.
At CPC+CBEx, we bring together...
08/07/2024
Journal of Clinical Pathways
Farrukh Awan, MD
Videos
Chronic Lymphocytic Leukemia Treatment Updates
07/31/2024
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.
Farrukh Awan, MD, discusses some...
07/31/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Why People Should Care About How Health Care Works (Part 1)
07/29/2024
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, dive into the topic of big data: what it is, how it came about, and why we’re still struggling to leverage it.
In part one of this two-part...
07/29/2024
Cancer Care Business Exchange
Ivy Altomare, MD
Videos
Characteristics of Clinical Trials in Community Oncology Practices Across the US
07/23/2024
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an overview of her study on the characteristics of clinical trials carried out in community oncology practices within the Flatiron Health network in the US.
Ivy Altomare, MD, provides an...
07/23/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
Sandip Patel, MD
Videos
Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape
07/22/2024
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.
Sandip Patel, MD, discusses the...
07/22/2024
Journal of Clinical Pathways
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
BDHC thumbnail
Breaking Down Health Care
Show Me the Medical Evidence
07/15/2024
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health Care conversation, John Hennessy, MBA, and Michael Kolodziej, MD, talk about the challenges of practicing medicine and keeping up with treatment developments when the evidence is constantly changing and evolving.
In this Breaking Down Health...
07/15/2024
Cancer Care Business Exchange
Gunjan Sharma
Interview
Leveraging Data to Enhance Patient Care: Addressing Social Determinants of Health in Oncology Care
07/10/2024
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst Gunjan Sharma shares insights on the impact of health-related social needs, Beer’s criteria medication prescribing patterns, and how research can inform the development of support services for patients with cancer.
US Oncology Network analyst...
07/10/2024
Journal of Clinical Pathways
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways

Newsfeed

News
Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer
03/03/2023

Grace Taylor

Grace Taylor
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...
At the 2023 ASCO GU Cancers...
03/03/2023
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022

Craig Ostroff

Craig Ostroff
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022

Craig Ostroff

Craig Ostroff
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
News
Real-World Risk of Infusion Reactions and Efficacy of Frontline Obinutuzumab-Chlorambucil for CLL
02/10/2022

Marta Rybczynski

Marta Rybczynski
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of infusion reactions in patients with CLL receiving obinutuzumab can be reduced using chlorambucil before obinutuzumab administration and by using a slow initial obinutuzumab infusion rate.
Study findings suggest risk of...
02/10/2022
Journal of Clinical Pathways
News
Real-World Utilization of and Spending on New Targeted Cancer Drugs in the United States
11/03/2021

Marta Rybczynski

Marta Rybczynski
A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.
A real-world study suggests that cancer drugs without documented OS benefits are increasingly adopted in the health system, accounting for substantial spending.
A real-world study suggests that...
11/03/2021
Journal of Clinical Pathways
News
Maintenance Therapy Patterns for Recurrent Ovarian Cancer in Real-World Setting
08/04/2021
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world suggest maintenance therapy is becoming more common following second- or third-line platinum-based chemotherapy for ovarian cancer, regardless of biomarker status.
Findings from a real-world...
08/04/2021
Journal of Clinical Pathways
News
Real-World Patterns and Predictors of Oral Anticancer Agent Use Among Patients With Metastatic RCC
07/29/2021
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral anticancer agent use in patients with mRCC is low, especially in those with multiple comorbidities and high frailty.
Patterns and predictors of oral...
07/29/2021
Journal of Clinical Pathways
News
Real-World Impact of Baseline Risk Factors on Incidence of Febrile Neutropenia in Patients With Breast Cancer
07/28/2021
Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...
Findings from a real-world study show the choice of febrile neutropenia definition significantly changed the impact of risk factors on febrile neutropenia outcomes among patients with breast cancer receiving chemotherapy with pegfilgrastim...
Findings from a real-world study...
07/28/2021
Journal of Clinical Pathways
News
Real-World Health Care Utilization and Costs in the Huntsman at Home Program
06/02/2021
A recent study found that an oncology hospital at home program model may lower unplanned health care utilization and health care costs for patients with cancer.
A recent study found that an oncology hospital at home program model may lower unplanned health care utilization and health care costs for patients with cancer.
A recent study found that an...
06/02/2021
Journal of Clinical Pathways
News
Real-World Treatment Discontinuation Among Patients With CLL
05/13/2021
05/13/2021
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
News
GE HealthCare Introduces New Precision Care Tools to Expand Access to Personalized Medicine
06/10/2024
Grace Taylor, MS, MA
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare premiered its new precision care tools to expand the practice of more personalized medicine internationally.
General Electric (GE) HealthCare...
06/10/2024
Journal of Clinical Pathways
News
Phase 3 KEYNOTE-522 Trial Meets Overall Survival Endpoints in Patients With TNBC
05/30/2024
Grace Taylor, MS, MA
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase 3 KEYNOTE-522 trial evaluating pembrolizumab (Keytruda) met its overall survival endpoint for treating patients with high-risk early-state triple-negative breast cancer (TNBC).
Merck announced that their phase...
05/30/2024
Journal of Clinical Pathways
News
Ajax Therapeutics Receives FDA Clearance to Initiate Phase 1 Clinical Study of AJ1-11095 for Myelofibrosis
05/23/2024
Grace Taylor, MS, MA
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received clearance from the US Food and Drug Administration (FDA) to begin a phase 1 clinical study of AJ1-11095, a first-in-class type 2 JAK2 inhibitor, for treating myelofibrosis.
Ajax Therapeutics received...
05/23/2024
Journal of Clinical Pathways
News
Patients With Breast Cancer Experience High Economic Burden and Lower HRQoL: Literature Review
05/15/2024
Grace Taylor, MS, MA
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review summarizes the economic and health-related quality of life (HRQoL) outcomes experienced by patients with early-stage hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative...
A systematic literature review...
05/15/2024
Journal of Clinical Pathways

Interactive Features

SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Scott Swain, PhD.
Videos
Navigating the FDA’s Guidance on Real-World Evidence: Insights, Expectations, and Future Trends in Clinical Trials
02/02/2024

Featuring Scott Swain, PhD, MPH

Featuring Scott Swain, PhD, MPH ...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director of real-world evidence & regulatory science at Cardinal Health, provides context and shares insights on the FDA's recently released guidance on the use of real-world data and real-world evidence in...
Scott Swain, PhD, MPH, director...
02/02/2024
Journal of Clinical Pathways
Conference Coverage
The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration
12/06/2023

Edited by Grace Taylor

Edited by Grace Taylor
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...
Using data from a real-world...
12/06/2023
Journal of Clinical Pathways
Video thumbnail screenshot.
Videos
Using Digital Health to Implement Patient-Reported Outcomes in Cancer Care
08/30/2023

Featuring Claire Snyder, PhD, and Norah Crossnohere, PhD

Featuring Claire Snyder, PhD, and Nor...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns Hopkins Schools of Medicine and Public Health, and Norah Crossnohere, PhD, the Ohio State University College of Medicine, discuss their work on implementing patient-reported outcome measures into cancer care, and how...
Claire Snyder, PhD, Johns...
08/30/2023
Journal of Clinical Pathways
Christopher D'Avella, MD.
Videos
Using Provider Feedback to Improve Efficiency and Utilization of the Flatiron Assist EMR-Based Pathways Tool
08/14/2023

Featuring Christopher D'Avella, MD

Featuring Christopher D'Avella, MD ...
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks about his institution’s use of the Flatiron Assist pathways program, and how the improvements made to the tool as a result of provider feedback increased the efficiency and utilization of the program.
Christopher D’Avella, MD, talks...
08/14/2023
Journal of Clinical Pathways
Scott Swain, PhD.
Videos
Comparing Diversity in Real-World Evidence With Diversity in Clinical Trial and SEER Data
08/10/2023
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his study on comparison of diversity across real-world evidence with clinical trial and SEER data in patients with metastatic breast cancer.
Scott Swain, PhD, discusses his...
08/10/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement